Overdose of Etover in details
Risk of overdose increases with prolonged use of prednisone, particularly in large doses.
Symptoms: increased blood pressure, peripheral edema, increased side effects of the drug.
Treatment of acute overdose: an immediate gastric lavage or induction of vomiting, specific antidote is not found.
Treatment of chronic overdose: should reduce the dose of the drug.
Etover warnings
Prior to and during treatment with atorvastatin, especially if symptoms of liver damage, it is necessary to monitor liver function tests. With an increase in transaminase levels it should be monitored their activity up to normalization. If AST or ALT more than 3 times the norm persists, we recommend reducing the dose or withdrawal of atorvastatin.
When prompted during the treatment of symptoms of myopathy it should determine the activity of creatine kinase. If a significant increase in CK levels is preserved, it is recommended to reduce the dose of Eto or to cancel taking it.
The risk of myopathy during the treatment with atorvastatin increased, while the use of cyclosporine, fibrates, erythromycin, antifungal agents belonging to azoles, and niacin.
There is a likelihood of the following side effects, but not in all cases, a clear link with taking atorvastatin: muscle cramps, myositis, myopathy, paresthesia, peripheral neuropathy, pancreatitis, hepatitis, cholestatic jaundice, anorexia, vomiting, alopecia, pruritus, rash, impotence, hyperglycemia and hypoglycemia.
The children experience of atorvastatin using at a dose of 80 mg / day is restricted.
With careful use Eto in patients with chronic alcoholism.
Etover precautions
Use with caution in patients with infections, asthma, allergic disorders, haemorrhagic disorders, hypertension, and impaired renal, hepatic, cardiac function, history of peptic ulcer disease. Monitor for the development of blood, kidney, liver, or eye disorders. Elderly.
References
- DrugBank. "Etofenamate". http://www.drugbank.ca/drugs/DB08984 (accessed September 17, 2018).
- MeSH. "Anti-Inflammatory Agents, Non-Steroidal". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
